Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | TYMP | P19971 | 3/20 | 0.38 |
| ▸ | CTRC | Q99895 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941765 | 0.83 | KDM4E (0.35) | TYMPCTRCHCAR2KDM4EMAPK1 | |
| SCHEMBL1936139 | 0.77 | ALDH1A1 (0.42) | TYRKDM4ELIPGMAPT | |
| SCHEMBL22202362 | 0.77 | PPARA (0.45) | KDM4EMAPT | |
| SCHEMBL7983997 | 0.76 | LIPG (0.44) | CTRCNR1H2NR1H3LIPGMAPT | |
| SCHEMBL16976744 | 0.76 | ALDH1A1 (0.45) | TYRKDM4ELIPGMAPT | |
| SCHEMBL11776421 | 0.75 | LIPG (0.47) | NR1H2NR1H3LIPGMAPT | |
| SCHEMBL31230428 | 0.74 | TYR (0.53) | TYMPCTRCTYRKDM4ELIPG | |
| SCHEMBL1133572 | 0.74 | TYR (0.53) | TYMPCTRCTYRKDM4ELIPG | |
| Bromide SCHEMBL29257750 | 0.74 | LIPG (0.46) | NR1H2NR1H3LIPGMAPT | |
| SCHEMBL27823063 | 0.73 | LIPG (0.40) | CTRCTYRKDM4ELIPGMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197833-A1 | Silicon Containing Compounds Having Selective Cox-2 Inhibitory Activity and Methods of Making and Using the Same | ENGLEBIENNE & ASSOCIATES (BE) | 2009-08-06 | — | — | US | disclosed |
| US-7521435-B2 | Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same | PHARMA DIAGNOSTICS, N.V. (BE) | 2009-04-21 | — | — | US | disclosed |
| US-20060258619-A1 | Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same | PHARMA DIAGNOSTICS N.V. (BE) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258619-A1 | Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same | PTGS2, PTGES2, PTGS1 | SRC 1166/4885TYMP 515/4885CTRC 1772/4885 |
| US-20090197833-A1 | Silicon Containing Compounds Having Selective Cox-2 Inhibitory Activity and Methods of Making and Using the Same | PTGS2, PTGES2, PTGS1 | SRC 1166/4885TYMP 515/4885CTRC 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.